Seibold FW - Search Results

1

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.

Schölmerich J, Fellermann K, Seibold FW, Rogler G, Langhorst J, Howaldt S, Novacek G, Petersen AM, Bachmann O, Matthes H, Hesselbarth N, Teich N, Wehkamp J, Klaus J, Ott C, Dilger K, Greinwald R, Mueller R; International TRUST-2 Study Group. Schölmerich J, et al. Among authors: seibold fw. J Crohns Colitis. 2017 Apr 1;11(4):390-399. doi: 10.1093/ecco-jcc/jjw184. J Crohns Colitis. 2017. PMID: 27707789 Free PMC article. Clinical Trial.

2

What is the optimal maintenance treatment for Crohn's disease?

Seibold F. Seibold F. Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S255-6. doi: 10.1002/ibd.20672. Inflamm Bowel Dis. 2008. PMID: 18816744 No abstract available.

3

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.

Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P; Swiss IBDnet. Schoepfer AM, et al. Inflamm Bowel Dis. 2010 Jun;16(6):933-8. doi: 10.1002/ibd.21127. Inflamm Bowel Dis. 2010. PMID: 20014021 Clinical Trial.

4

Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness.

Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F; Swiss IBD Cohort Study Group. Juillerat P, et al. Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1352-7. doi: 10.1097/meg.0b013e32833eaa8a. Eur J Gastroenterol Hepatol. 2010. PMID: 20964261

5

Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.

Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P; Swiss IBDnet. Vavricka SR, et al. Inflamm Bowel Dis. 2011 Jul;17(7):1530-9. doi: 10.1002/ibd.21521. Epub 2010 Dec 22. Inflamm Bowel Dis. 2011. PMID: 21674709 Clinical Trial.

6

Treatment algorithm for moderate to severe ulcerative colitis.

Manz M, Michetti P, Seibold F, Rogler G, Beglinger C. Manz M, et al. Swiss Med Wkly. 2011 Jun 27;141:w13235. doi: 10.4414/smw.2011.13235. eCollection 2011. Swiss Med Wkly. 2011. PMID: 21706453 Free article. Review.

7

[Topical therapy of ulcerative colitis].

Rogler G, Beglinger C, Mottet C, Seibold F, Gross V. Rogler G, et al. Praxis (Bern 1994). 2011 Nov 16;100(23):1413-24. doi: 10.1024/1661-8157/a000722. Praxis (Bern 1994). 2011. PMID: 22086380 Review. German.

8

Increased titers of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients with reduced H-ficolin levels but normal MASP-2 activity.

Schaffer T, Flogerzi B, Schoepfer AM, Seibold F, Müller S. Schaffer T, et al. J Crohns Colitis. 2013 Feb;7(1):e1-10. doi: 10.1016/j.crohns.2012.02.013. Epub 2012 Mar 23. J Crohns Colitis. 2013. PMID: 22445443

9

Pregnancy and breastfeeding in inflammatory bowel disease.

Biedermann L, Rogler G, Vavricka SR, Seibold F, Seirafi M. Biedermann L, et al. Digestion. 2012;86 Suppl 1:45-54. doi: 10.1159/000341941. Epub 2012 Oct 5. Digestion. 2012. PMID: 23051726 Free article. Review.

10

Topical therapy is underused in patients with ulcerative colitis.

Seibold F, Fournier N, Beglinger C, Mottet C, Pittet V, Rogler G; Swiss IBD cohort study group. Seibold F, et al. J Crohns Colitis. 2014 Jan;8(1):56-63. doi: 10.1016/j.crohns.2013.03.005. Epub 2013 Apr 6. J Crohns Colitis. 2014. PMID: 23566922 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127 results

Search Page